Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.41 |
| ▸ | FEN1 | P39748 | 4/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 2/20 | 0.35 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.35 |
| ▸ | MICA | Q29983 | 1/20 | 0.35 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25341479 | 0.87 | ALPL (0.46) | ALOX5APFEN1SMN1; SMN2 | |
| SCHEMBL25341077 | 0.86 | ALOX5AP (0.38) | ALOX5APFEN1FTOCOMTERAP1 | |
| SCHEMBL30519329 | 0.86 | ALOX5AP (0.38) | ALOX5APFEN1FTOCOMTERAP1 | |
| SCHEMBL25339100 | 0.81 | LMNA (0.43) | ALOX5APFEN1FTOCOMTERAP1 | |
| SCHEMBL30519237 | 0.76 | ALOX5AP (0.43) | ALOX5APFEN1ERAP1TRPV1P2RX1 | |
| SCHEMBL30519397 | 0.76 | MMP13 (0.35) | FTOCOMTERAP1TRPV1SMN1; SMN2 | |
| SCHEMBL25339584 | 0.76 | MMP13 (0.35) | FTOCOMTERAP1TRPV1SMN1; SMN2 | |
| SCHEMBL25341566 | 0.76 | ALOX5AP (0.43) | ALOX5APFEN1ERAP1TRPV1P2RX1 | |
| SCHEMBL25340680 | 0.74 | WDR5 (0.39) | TRPV1 | |
| SCHEMBL30519324 | 0.74 | WDR5 (0.39) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |